We summarized the existing metabolic targets used in DMARDS and highlighted several future potential targets to treat autoimmune diseases including mTOR, GCN2, IDO1, ARG 1, kynurenine, cysteine, S1P receptor and fatty acid enzymes. This evidence concerns the gene EIF2AK4 and autoimmune disease.